RT Journal Article
SR Electronic
T1 Metabolic imaging across scales reveals distinct prostate cancer phenotypes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.29.23296228
DO 10.1101/2023.09.29.23296228
A1 Sushentsev, Nikita
A1 Hamm, Gregory
A1 Flint, Lucy
A1 Birtles, Daniel
A1 Zakirov, Aleksandr
A1 Richings, Jack
A1 Ling, Stephanie
A1 Tan, Jennifer Y.
A1 McLean, Mary A.
A1 Ayyappan, Vinay
A1 Menih, Ines Horvat
A1 Brodie, Cara
A1 Miller, Jodi L.
A1 Mills, Ian G.
A1 Gnanapragasam, Vincent J.
A1 Warren, Anne Y.
A1 Barry, Simon T.
A1 Goodwin, Richard J.A.
A1 Barrett, Tristan
A1 Gallagher, Ferdia A.
YR 2023
UL http://medrxiv.org/content/early/2023/10/02/2023.09.29.23296228.abstract
AB Hyperpolarised magnetic resonance imaging (HP-13C-MRI) has shown promise as a clinical tool for detecting and characterising prostate cancer. Here we have used a range of spatially resolved histological techniques to identify the biological mechanisms underpinning differential [1-13C]lactate labelling between benign and malignant prostate, as well as tumours containing cribriform and non-cribriform Gleason pattern 4 disease. The elevated hyperpolarised [1-13C]lactate signal in prostate cancer compared to the benign prostate is primarily driven by increased tumour epithelial cell density and vascularity, rather than differences in epithelial lactate concentration between tumour and normal. We also demonstrate that tumours of the cribriform subtype may lack [1-13C]lactate labelling, which is explained by their lower epithelial lactate dehydrogenase expression, higher mitochondrial pyruvate carrier density, and increased lipid abundance compared to lactate-rich non-cribriform lesions. These findings highlight the potential of combining spatial metabolic imaging tools across scales to identify novel metabolic phenotypes in prostate cancer.Competing Interest StatementGH, LF, DB, JR, SL, JYT, STB, and RJAG are AstraZeneca employees. F.A.G. has research support from GE Healthcare, grants from GlaxoSmithKline, and has consulted for AstraZeneca on behalf of the University of Cambridge. The remaining authors declare no competing interests.Funding StatementThis study was supported by Prostate Cancer UK (PCUK; Grant PA14-012) and Cancer Research UK (CRUK; Grant C197/A16465), Cancer Research UK Cambridge Centre, the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre (NIHR203312), AstraZeneca, the Engineering and Physical Sciences Research Council Imaging Centre in Cambridge and Manchester, and the Cambridge Experimental Cancer Medicine Centre. N.S. is supported by the Gates Cambridge Trust. V.J.G. acknowledges infrastructure support from the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). A.Y.W. is supported by the Urological Malignancies Programme of the Cancer Research UK Cambridge Centre [C9685/A25177] and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided written consent to participate in the original prospective study (Molecular Imaging and Spectroscopy with Stable Isotopes in Oncology and Neurology - Imaging metabolism in prostate [MISSION-Prostate] protocol), retrospective analysis of which was approved by the institutional review board (National Research Ethics Service Committee East of England, Cambridge South, Research Ethics Committee number 16/EE/0205). To validate the key findings obtained in the HP-13C-MRI cohort by directly measuring tissue metabolite concentrations in fresh-frozen prostatectomy samples, we then retrospectively identified a secondary cohort of treatment-naive surgical patients who had been originally recruited into an ethically approved prospective national study (DIAMOND, National Research Ethics Service Committee East of England, Cambridge South, Research Ethics Committee number 03/018) following the provision of written consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors and subject to appropriate data transfer agreements.